357PPatient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease
Ettl, J, Quek, R G W, Bhattacharyya, H, Rugo, H S, Hurvitz, S A, Gonçalves, AVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.052
Date:
October, 2019
File:
PDF, 88 KB
2019